R
Richard C. Zink
Researcher at Bristol-Myers Squibb
Publications - 1
Citations - 1189
Richard C. Zink is an academic researcher from Bristol-Myers Squibb. The author has contributed to research in topics: HBeAg & Entecavir. The author has an hindex of 1, co-authored 1 publications receiving 1155 citations.
Papers
More filters
Journal ArticleDOI
Entecavir versus Lamivudine for Patients with HBeAg-Negative Chronic Hepatitis B
Ching-Lung Lai,Daniel Shouval,Anna S. Lok,Ting-Tsung Chang,Hugo Cheinquer,Zachary Goodman,Deborah DeHertogh,R B Wilber,Richard C. Zink,Anne Cross,Richard J. Colonno,Lori Fernandes +11 more
TL;DR: Among patients with HBeAg-negative chronic hepatitis B who had not previously been treated with a nucleoside analogue, the rates of histologic improvement, virologic response, and normalization of alanine aminotransferase levels were significantly higher at 48 weeks with entecavir than with lamivudine.